Nestlé Needs Growth Supplements, Maybe Not These Ones: Gadfly
When Dan Loeb called on Nestlé to overhaul its portfolio in June, the activist left the food giant room to make some acquisitions.
Now, according to Reuters, the Swiss company is looking at a purchase of Merck KGaA's consumer health business, best known for producing Seven Seas vitamins. The operation could be worth about €4 billion.
Nestlé CEO Ulf Mark Schneider should tread carefully: he risks paying a premium for a big bottle of pills for which he may not be able to go on charging steep prices.
It's not surprising why he might be interested. Nestlé's rate of sales growth has been anaemic. His firm's strategy is underpinned by a healthy dose of wellness. A purchase would boost Nestlé's nutrition and health science business, which accounted for 17% of sales at the half year, just as competitors are gaining scale.
GlaxoSmithKline is likely to buy out its consumer healthcare joint venture with Novartis next year. Reckitt Benckiser recently bought baby formula maker Mead Johnson for $18 billion, encroaching on Nestlé's turf.
The Merck business has been growing well ahead of the global economy, with organic revenue expanding at roughly 6% between 2013 and 2016. Sales were €860 million last year, implying a valuation of €4 billion it fetched the same multiple as Mead Johnson.
Can that growth last? It can make sense for consumer groups like Unilever and Danone to buy millennial-friendly brands like Dollar Shave Club and Alpro when the high prices paid are mitigated by the chance to shunt new high-margin products through a global sales network.
Vitamins are, however, a different proposition. Pricing power through branding is harder to achieve given the competition from super-cheap own-label alternatives. Seven Seas is already sold in more than 60 countries and claims market leadership in the UK. The brand dates back to 1935.
Moreover, moving into market for over-the-counter medicines would be a strategic departure for Nestlé, as Morgan Stanley analysts point out.
The risk is that an established player like Reckitt sees value in the Merck asset and nudges the price up through an auction. Reckitt has high leverage, with net debt expected to hit four times Ebitda at the year-end. But with a market capitalisation of £50 billion, even a modest placing of 5% of its equity could raise nearly €3 billion to fund a deal.
Schneider's background is in healthcare, having joined this year from Fresenius. Like his big consumer peers, he is struggling to achieve growth and will need to use M&A to buy it. But he must choose his growth supplements with care.